Archigen Biotech seeks FDA Approval for Rituximab Phase I Clinical Trials

Biosimilar News

The Korea Herald reports that Archigen Biotech, a joint venture between AstraZeneca UK and Samsung BioLogics, has applied for FDA approval to begin Phase I clinical trials for its rituximab biosimilar, SAIT101.

Archigen Biotech’s website states that clinical trials for SAIT101 are expected to begin globally in Q3 of 2016.

Download PDF

Comments are closed.